Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.131
Neutral
RSI(14)
43.305
Neutral
STOCH(KDJ)(9,3,3)
11.717
Oversold
ATR(14)
1.366
Low Volatility
CCI(14)
-142.543
Sell
Williams %R
67.767
Sell
TRIX(12,20)
0.388
Sell
StochRSI(14)
0.000
Oversold
Tonix Pharmaceuticals Holding Corp
TNXP17.070USD
-0.020-0.12%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
173.57MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Tonix Pharmaceuticals Holding Corp
Currency: USD Updated: 2025-12-19Key Insights
Tonix Pharmaceuticals Holding Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 119/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 66.33.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tonix Pharmaceuticals Holding Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
66.333
Target Price
+233.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Tonix Pharmaceuticals Holding Corp Highlights
StrengthsRisks
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.09M.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.83M shares, increasing 39.28% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 556.96K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Tonix Pharmaceuticals Holding Corp is 7.00, ranking 133/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 3.29M, representing a year-over-year increase of 16.58%, while its net profit experienced a year-over-year increase of 125.22%.
Score
Financials
9.94
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.60
Operational Efficiency
2.87
Growth Potential
7.46
Shareholder Returns
7.13
Tonix Pharmaceuticals Holding Corp's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Tonix Pharmaceuticals Holding Corp is 8.02, ranking 33/158 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -4840.00% below the recent high of 0.05 and -39650.00% above the recent low of -0.40.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 119/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Tonix Pharmaceuticals Holding Corp is 8.00, ranking 56/158 in the Pharmaceuticals industry. The average price target for Tonix Pharmaceuticals Holding Corp is 65.00, with a high of 70.00 and a low of 64.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
66.333
Target Price
+233.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Tonix Pharmaceuticals Holding Corp
TNXP
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Tonix Pharmaceuticals Holding Corp is 1.14, ranking 156/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 20.53 and the support level at 13.67, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
17.792
Sell
MA10
18.608
Sell
MA20
17.654
Sell
MA50
17.924
Sell
MA100
25.346
Sell
MA200
26.996
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Tonix Pharmaceuticals Holding Corp is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 18.40%, representing a quarter-over-quarter increase of 96.79%. The largest institutional shareholder is The Vanguard, holding a total of 556.96K shares, representing 4.73% of shares outstanding, with 255.51% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
Northern Trust Investments, Inc.
State Street Investment Management (US)
Fidelity Management & Research Company LLC
UBS Financial Services, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Tonix Pharmaceuticals Holding Corp is 3.14, ranking 105/158 in the Pharmaceuticals industry. The company's beta value is 1.73. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.78
VaR
+9.62%
240-Day Maximum Drawdown
+83.96%
240-Day Volatility
+159.67%
Return
Best Daily Return
60 days
+14.56%
120 days
+32.89%
5 years
+100.00%
Worst Daily Return
60 days
-11.27%
120 days
-21.97%
5 years
-100.00%
Sharpe Ratio
60 days
-1.80
120 days
-1.07
5 years
-0.59
Risk Assessment
Maximum Drawdown
240 days
+83.96%
3 years
+99.97%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.54
3 years
-0.33
5 years
-0.20
Skewness
240 days
-0.19
3 years
+1.19
5 years
+1.82
Volatility
Realised Volatility
240 days
+159.67%
5 years
+159.31%
Standardised True Range
240 days
+18.51%
5 years
+48799.70%
Downside Risk-Adjusted Return
120 days
-186.74%
240 days
-186.74%
Maximum Daily Upside Volatility
60 days
+60.36%
Maximum Daily Downside Volatility
60 days
+46.65%
Liquidity
Average Turnover Rate
60 days
+19.87%
120 days
+600.43%
5 years
--
Turnover Deviation
20 days
-99.88%
60 days
-99.92%
120 days
-97.48%
Peer Comparison
Pharmaceuticals
Tonix Pharmaceuticals Holding Corp
TNXP
5.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Tonix Pharmaceuticals Holding Corp?
The TradingKey Stock Score provides a comprehensive assessment of Tonix Pharmaceuticals Holding Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Tonix Pharmaceuticals Holding Corp’s performance and outlook.
How do we generate the financial health score of Tonix Pharmaceuticals Holding Corp?
To generate the financial health score of Tonix Pharmaceuticals Holding Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Tonix Pharmaceuticals Holding Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Tonix Pharmaceuticals Holding Corp.
How do we generate the company valuation score of Tonix Pharmaceuticals Holding Corp?
To generate the company valuation score of Tonix Pharmaceuticals Holding Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Tonix Pharmaceuticals Holding Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Tonix Pharmaceuticals Holding Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Tonix Pharmaceuticals Holding Corp.
How do we generate the earnings forecast score of Tonix Pharmaceuticals Holding Corp?
To calculate the earnings forecast score of Tonix Pharmaceuticals Holding Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Tonix Pharmaceuticals Holding Corp’s future.
How do we generate the price momentum score of Tonix Pharmaceuticals Holding Corp?
When generating the price momentum score for Tonix Pharmaceuticals Holding Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Tonix Pharmaceuticals Holding Corp’s prices. A higher score indicates a more stable short-term price trend for Tonix Pharmaceuticals Holding Corp.
How do we generate the institutional confidence score of Tonix Pharmaceuticals Holding Corp?
To generate the institutional confidence score of Tonix Pharmaceuticals Holding Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Tonix Pharmaceuticals Holding Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Tonix Pharmaceuticals Holding Corp.
How do we generate the risk management score of Tonix Pharmaceuticals Holding Corp?
To assess the risk management score of Tonix Pharmaceuticals Holding Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Tonix Pharmaceuticals Holding Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Tonix Pharmaceuticals Holding Corp.
